Examining a new therapy for adolescents with low weight eating disorders
A Confirmatory Efficacy Study of Interoceptive Exposure for Adolescents with Low Weight Eating Disorders
This study is testing a new therapy called family-based interoceptive exposure (FBT-E) to see if it helps teenagers with low weight eating disorders, like anorexia, feel better and gain weight compared to the usual family-based therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11013332 on NIH RePORTER |
What this research studies
This research investigates a novel therapy called family-based interoceptive exposure (FBT-E) for adolescents suffering from low weight eating disorders like anorexia nervosa. The study aims to compare the effectiveness of FBT-E against traditional family-based therapy (FBT) in improving weight and reducing eating disorder symptoms over a 12-month period. Participants will be adolescents aged 12-18, and the research will involve a randomized controlled trial to assess both short-term and long-term outcomes. The approach focuses on reducing food avoidance and enhancing body awareness through targeted therapeutic techniques.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents aged 12-18 who are diagnosed with low weight eating disorders such as anorexia nervosa.
Not a fit: Patients who are outside the age range of 12-18 or those not diagnosed with low weight eating disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for adolescents with low weight eating disorders, improving their overall health and quality of life.
How similar studies have performed: Preliminary data from earlier studies suggest that similar therapeutic approaches have shown promise, indicating potential for success in this confirmatory trial.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hildebrandt, Thomas B — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hildebrandt, Thomas B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.